|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.10 CNY | +1.30% |
|
+7.40% | -8.37% |
| 01:22pm | China Includes Hubei Jumpcan Pharmaceutical's Granules for Colds in Children in Essential Drug List | MT |
| 09/06 | Jumpcan Pharma Gets Registration Certificate for Marboxil Tablets | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 9.22 | 10.39 | 10.88 | 8.28 | 6.41 | |||||
Return on Total Capital | 11.52 | 13.1 | 13.75 | 10.1 | 7.5 | |||||
Return On Equity % | 20.33 | 21.2 | 22.87 | 18.06 | 12.11 | |||||
Return on Common Equity | 20.37 | 21.23 | 22.87 | 18.05 | 12.13 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 83.27 | 82.91 | 81.52 | 79.21 | 78.95 | |||||
SG&A Margin | 52.82 | 49.76 | 45.36 | 42.25 | 41.15 | |||||
EBITDA Margin % | 25.67 | 28.41 | 32.94 | 34.01 | 34.63 | |||||
EBITA Margin % | 22.09 | 25.26 | 30.07 | 30.53 | 30.23 | |||||
EBIT Margin % | 21.89 | 25.05 | 29.87 | 30.26 | 29.82 | |||||
Income From Continuing Operations Margin % | 22.5 | 24.14 | 29.28 | 31.64 | 28.6 | |||||
Net Income Margin % | 22.53 | 24.13 | 29.24 | 31.58 | 28.59 | |||||
Net Avail. For Common Margin % | 22.53 | 24.13 | 29.24 | 31.58 | 28.59 | |||||
Normalized Net Income Margin | 14.82 | 16.7 | 20.82 | 21.38 | 21.09 | |||||
Levered Free Cash Flow Margin | 13.27 | 18.23 | 23.6 | 16.17 | 19.74 | |||||
Unlevered Free Cash Flow Margin | 13.55 | 18.44 | 23.71 | 16.38 | 19.86 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.67 | 0.66 | 0.58 | 0.44 | 0.34 | |||||
Fixed Assets Turnover | 2.47 | 3.05 | 3.34 | 2.85 | 2.41 | |||||
Receivables Turnover (Average Receivables) | 3.61 | 3.57 | 3.42 | 3.17 | 2.84 | |||||
Inventory Turnover (Average Inventory) | 3.9 | 4.01 | 4.05 | 3.15 | 2.98 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.9 | 3.26 | 3.1 | 4.16 | 4.93 | |||||
Quick Ratio | 2.75 | 3.13 | 2.99 | 3.99 | 4.81 | |||||
Operating Cash Flow to Current Liabilities | 0.68 | 0.76 | 0.75 | 0.62 | 0.42 | |||||
Days Sales Outstanding (Average Receivables) | 100.97 | 102.33 | 106.64 | 115.32 | 128.45 | |||||
Days Outstanding Inventory (Average Inventory) | 93.5 | 91.06 | 90.18 | 116.31 | 122.5 | |||||
Average Days Payable Outstanding | 153.83 | 287.97 | 353.45 | 405.85 | 529.2 | |||||
Cash Conversion Cycle (Average Days) | 40.64 | -94.59 | -156.62 | -174.22 | -278.25 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 6.9 | 3.53 | 8.15 | 5.69 | 4.91 | |||||
Total Debt / Total Capital | 6.46 | 3.41 | 7.54 | 5.39 | 4.68 | |||||
LT Debt/Equity | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |||||
Long-Term Debt / Total Capital | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |||||
Total Liabilities / Total Assets | 24.73 | 24.22 | 26.32 | 20.22 | 17.33 | |||||
EBIT / Interest Expense | 47.87 | 74.12 | 163.99 | 88.94 | 162.01 | |||||
EBITDA / Interest Expense | 56.15 | 84.11 | 180.95 | 100.03 | 188.26 | |||||
(EBITDA - Capex) / Interest Expense | 49.04 | 76.1 | 163.8 | 93.64 | 179.89 | |||||
Total Debt / EBITDA | 0.32 | 0.16 | 0.34 | 0.31 | 0.33 | |||||
Net Debt / EBITDA | -2.48 | -2.92 | -3.09 | -4.03 | -5.1 | |||||
Total Debt / (EBITDA - Capex) | 0.37 | 0.17 | 0.38 | 0.33 | 0.35 | |||||
Net Debt / (EBITDA - Capex) | -2.84 | -3.22 | -3.41 | -4.3 | -5.33 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 23.77 | 17.9 | 7.32 | -16.96 | -22.43 | |||||
Gross Profit, 1 Yr. Growth % | 26.2 | 17.39 | 5.52 | -19.31 | -22.69 | |||||
EBITDA, 1 Yr. Growth % | 17.58 | 30.17 | 24.19 | -14.38 | -21.21 | |||||
EBITA, 1 Yr. Growth % | 20.17 | 34.43 | 27.52 | -15.82 | -23.41 | |||||
EBIT, 1 Yr. Growth % | 20.6 | 34.91 | 27.94 | -15.88 | -23.58 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 34.45 | 26.47 | 30.18 | -10.27 | -29.9 | |||||
Net Income, 1 Yr. Growth % | 34.6 | 26.27 | 30.04 | -10.32 | -29.77 | |||||
Normalized Net Income, 1 Yr. Growth % | 26.15 | 32.83 | 33.79 | -14.75 | -23.5 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 24.84 | 25.13 | 28.87 | -10.39 | -30.07 | |||||
Accounts Receivable, 1 Yr. Growth % | 7.44 | 30.58 | -2.41 | -18.84 | -6.56 | |||||
Inventory, 1 Yr. Growth % | 34.9 | 4.23 | 25.19 | 16.12 | -45.59 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -3.4 | -5.86 | 2.32 | -7.4 | -9.67 | |||||
Total Assets, 1 Yr. Growth % | 15.36 | 23.49 | 21.11 | 1.74 | -4.11 | |||||
Tangible Book Value, 1 Yr. Growth % | 18.57 | 25.14 | 18.69 | 10.47 | -0.88 | |||||
Common Equity, 1 Yr. Growth % | 17.44 | 24.36 | 17.75 | 10.13 | -0.66 | |||||
Cash From Operations, 1 Yr. Growth % | 6.32 | 38.35 | 32.17 | -37.17 | -44.94 | |||||
Capital Expenditures, 1 Yr. Growth % | -42.2 | -1.88 | 23.8 | -42.21 | -45.01 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 11.37 | 61.99 | 38.92 | -43.09 | -5.34 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 11.24 | 60.42 | 37.99 | -42.62 | -6.02 | |||||
Dividend Per Share, 1 Yr. Growth % | 51.11 | 29.41 | 47.73 | 60.77 | -16.75 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 4.86 | 20.8 | 12.48 | -5.6 | -19.74 | |||||
Gross Profit, 2 Yr. CAGR % | 4.4 | 21.72 | 11.3 | -7.73 | -21.02 | |||||
EBITDA, 2 Yr. CAGR % | -1.89 | 23.86 | 27.26 | 3.19 | -17.77 | |||||
EBITA, 2 Yr. CAGR % | -3.93 | 27.27 | 31.07 | 3.69 | -19.59 | |||||
EBIT, 2 Yr. CAGR % | -3.73 | 27.56 | 31.38 | 3.74 | -19.8 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 2.86 | 30.4 | 28.31 | 8.08 | -20.69 | |||||
Net Income, 2 Yr. CAGR % | 2.92 | 30.37 | 28.14 | 7.99 | -20.64 | |||||
Normalized Net Income, 2 Yr. CAGR % | -0.71 | 29.45 | 33.31 | 6.8 | -19.23 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -2.03 | 24.98 | 26.99 | 7.46 | -20.84 | |||||
Accounts Receivable, 2 Yr. CAGR % | 3.07 | 18.45 | 12.88 | -11 | -12.92 | |||||
Inventory, 2 Yr. CAGR % | 5.34 | 18.58 | 14.23 | 20.57 | -20.51 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 0.26 | -4.64 | -1.86 | -2.66 | -8.54 | |||||
Total Assets, 2 Yr. CAGR % | 18.32 | 19.36 | 22.3 | 11 | -1.23 | |||||
Tangible Book Value, 2 Yr. CAGR % | 24.41 | 21.81 | 21.87 | 14.51 | 4.64 | |||||
Common Equity, 2 Yr. CAGR % | 22.21 | 20.85 | 21.01 | 13.88 | 4.6 | |||||
Cash From Operations, 2 Yr. CAGR % | -6.08 | 21.28 | 35.23 | -8.87 | -41.18 | |||||
Capital Expenditures, 2 Yr. CAGR % | -32.59 | -24.69 | 10.22 | -15.41 | -43.63 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -11.83 | 34.32 | 50.01 | -11.09 | -26.59 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -11.54 | 33.59 | 48.78 | -11.02 | -26.55 | |||||
Dividend Per Share, 2 Yr. CAGR % | -25.65 | 39.84 | 38.27 | 54.11 | 15.69 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 1.92 | 9.04 | 16.13 | 1.66 | -11.58 | |||||
Gross Profit, 3 Yr. CAGR % | 1.3 | 8.56 | 16.06 | -0.02 | -13.01 | |||||
EBITDA, 3 Yr. CAGR % | -1.37 | 7.9 | 24.05 | 11.56 | -5.61 | |||||
EBITA, 3 Yr. CAGR % | -3.73 | 7.55 | 27.45 | 13.14 | -6.18 | |||||
EBIT, 3 Yr. CAGR % | -3.63 | 7.73 | 27.69 | 13.24 | -6.29 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 0.58 | 10.2 | 30.32 | 13.89 | -6.45 | |||||
Net Income, 3 Yr. CAGR % | 0.61 | 10.18 | 30.26 | 13.77 | -6.44 | |||||
Normalized Net Income, 3 Yr. CAGR % | -1.37 | 9.4 | 30.88 | 14.85 | -4.43 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -2.65 | 6.3 | 26.27 | 13.06 | -6.88 | |||||
Accounts Receivable, 3 Yr. CAGR % | 1.2 | 11.53 | 11.04 | 1.13 | -9.55 | |||||
Inventory, 3 Yr. CAGR % | 5.69 | 4.97 | 20.74 | 14.86 | -7.52 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 2.54 | -1.82 | -2.37 | -3.74 | -5.05 | |||||
Total Assets, 3 Yr. CAGR % | 15.87 | 20.02 | 19.94 | 15.02 | 5.72 | |||||
Tangible Book Value, 3 Yr. CAGR % | 20.38 | 24.65 | 20.76 | 17.95 | 9.13 | |||||
Common Equity, 3 Yr. CAGR % | 18.65 | 22.92 | 19.8 | 17.27 | 8.81 | |||||
Cash From Operations, 3 Yr. CAGR % | 3.49 | 6.86 | 24.81 | 4.74 | -22.96 | |||||
Capital Expenditures, 3 Yr. CAGR % | -28.1 | -23.6 | -11.12 | -11.12 | -26.73 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 88.96 | 7.99 | 35.83 | 8.59 | -9.2 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 82.06 | 7.88 | 35.04 | 8.3 | -9.37 | |||||
Dividend Per Share, 3 Yr. CAGR % | -17.93 | -10.56 | 42.42 | 45.39 | 25.51 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 10.28 | 9.78 | 6.02 | 2.93 | 0.17 | |||||
Gross Profit, 5 Yr. CAGR % | 9.77 | 9.25 | 5.19 | 1.73 | -0.5 | |||||
EBITDA, 5 Yr. CAGR % | 11.12 | 11.23 | 9.27 | 6.03 | 5.27 | |||||
EBITA, 5 Yr. CAGR % | 9.76 | 10.66 | 8.98 | 6.04 | 6.03 | |||||
EBIT, 5 Yr. CAGR % | 9.96 | 10.81 | 9.09 | 6.12 | 6.01 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 12.94 | 12.15 | 10.87 | 9.34 | 6.84 | |||||
Net Income, 5 Yr. CAGR % | 12.97 | 12.15 | 10.83 | 9.3 | 6.84 | |||||
Normalized Net Income, 5 Yr. CAGR % | 11.37 | 10.9 | 11.26 | 8.35 | 7.9 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 10.3 | 9.62 | 8.27 | 6.76 | 4.75 | |||||
Accounts Receivable, 5 Yr. CAGR % | 8.89 | 9.56 | 5.72 | 1.9 | 0.75 | |||||
Inventory, 5 Yr. CAGR % | 12.94 | 10.06 | 9.02 | 10.95 | 2.15 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 12.38 | 4.24 | 0.76 | -2.16 | -4.89 | |||||
Total Assets, 5 Yr. CAGR % | 19.45 | 17.59 | 18.4 | 16.33 | 10.98 | |||||
Tangible Book Value, 5 Yr. CAGR % | 21.57 | 22.01 | 20.98 | 20.49 | 14.04 | |||||
Common Equity, 5 Yr. CAGR % | 20.04 | 20.83 | 19.59 | 19.22 | 13.47 | |||||
Cash From Operations, 5 Yr. CAGR % | 15.71 | 17.13 | 15.18 | 0.27 | -7.63 | |||||
Capital Expenditures, 5 Yr. CAGR % | -5.15 | -20.06 | -14.7 | -20.43 | -25.92 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 15.4 | 84.98 | 72.3 | -0.09 | 6.2 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 15.89 | 83.77 | 67.94 | -0.12 | 5.84 | |||||
Dividend Per Share, 5 Yr. CAGR % | -1.41 | -2.52 | 1.11 | 11.19 | 31.06 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















